Published in
Taylor and Francis Group, Leukemia & Lymphoma, 14(63), p. 3488-3492, 2022
DOI: 10.1080/10428194.2022.2131417
Links
Tools
A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy
Journal article published in 2022 by
Karthik Nath 
,
Tala Shekarkhand,
Meghan Salcedo,
Andriy Derkach,
Siobhan Rueda,
Aisara Chansakul,
Malin Hulcrantz,
Neha Korde ,
Urvi A. Shah ,
Carlyn Tan ,
David J. Chung ,
Oscar B. Lahoud ,
Hani Hassoun ,
Alexander M. Lesokhin ,
Heather J. Landau
and other authors.
,
Tala Shekarkhand,
Meghan Salcedo,
Andriy Derkach,
Siobhan Rueda,
Aisara Chansakul,
Malin Hulcrantz,
Neha Korde ,
Urvi A. Shah ,
Carlyn Tan ,
David J. Chung ,
Oscar B. Lahoud ,
Hani Hassoun ,
Alexander M. Lesokhin ,
Heather J. Landau
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 